Medication Monitor



Generic Name (Trade Name—Company)
Notes
May 1, 2019

Bevacizumab 1.25 mg/0.05 mL 31G injectable

(No trade name—AmEx Pharmacy)
Recalled lot has defective delivery system that may cause injury

AmEx Pharmacy is voluntarily recalling one lot (#190212AB, BUD 5/13/2019) of bevacizumab 1.25 mg/0.05 mL 31G injectable to the consumer/user level. The monoject syringe of this product may become difficult to express, and the additional force needed to express the drug product could result in damage to the eye while the needle is in the eye. 

The product is used for wet age-related macular degeneration and diabetic retinopathy. It is individually wrapped and labeled in a Tyvek pouch, which is then placed in a labeled amber bag to protect from light. The lot number appears prominently on all labeling. The lot was distributed to ophthalmologist clinics in Pennsylvania, Illinois, Texas, Wisconsin, Kansas, Tennessee, Indiana, and Arizona.

To date, AmEx Pharmacy has received three reports, two of which resulted in an adverse drug event.